NextCure, Inc.

Sentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b

Kronos Bio Inc. left most of its employees with little to be thankful for on 27 November when it announced a day before the Thanksgiving holiday in the US that in addition to CEO Norbert Bischofberger

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Biocytogen Licenses Antibodies For

NextCure, Inc. got off to a strong start, with the best-performing initial public offering in the US in 2019 and rising to six times its initial stock price in November based on two responses in lung